CLINICAL_TRIALS
trial_result
· 2019-01-31
Clinical Trial Update: Sunitinib in Refractory Adrenocortical Carcinoma [Phase 2]
Summary
A Phase 2 trial of sunitinib in patients with refractory adrenocortical carcinoma has completed, with results posted in January 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Wuerzburg | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-31